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Abstract
Tobacco use is the greatest threat to public health worldwide,
killing more than seven million people annually. This paper, about
10 years after the first review on electronic cigarettes, analyses the
evolution that this tool has had in these years. It concludes with
comments on the significance of the research and why it consti-
tutes an original contribution. We searched PubMed (National
Library of Medicine), and PsycINFO (Ovid) (2006-2020) for stud-
ies on e-cigarettes (harms and benefits, e-cigarette use, craving
and smoking cessation) and smoking cessation treatment (smok-
ing cessation treatment or varenicline or tobacco cessation or
reduction or bupropion or NRT or behavioral treatment or e-
cigarette) and evidence suggests that they may effective as smok-
ing cessation tool and may be less harmful alternatives to com-
bustible cigarette smoking. Consequently, e-cigarettes could be
considered as an applicable instrument for Tobacco Harm
Reduction (THR) and smoking cessation. 
Introduction
Amongst the World Health Organization (WHO) regions, in
2015, over 1.1 billion people smoked tobacco. Far more males
(36.1%) than females (6.8%) smoked tobacco. Although it is
declining worldwide and in many countries, the prevalence of
tobacco smoking appears to be increasing in the WHO Eastern
Mediterranean Region and the African Region. Amongst the
WHO regions Europe has the highest prevalence of tobacco smok-
ing amongst adults (28%) (WHO, 2018). In Italy, adult smoking
prevalence has consistently decreased since recording started in
1957 (Gallus, Lugo, Colombo, Pacifici, La Vecchia, 2013). From
2013 to 2014, Lugo et al. (2015) found an overall smoking preva-
lence amongst Italian adults of 21% (26% of men and 17% of
women). This agrees with recent data from a large household sur-
vey (based on 60,000 families and 130,000 individuals) conducted
in 2013 by the National Institute of Statistics (ISTAT), showing an
adult smoking rate of 21% (26% in men and 16% in women)
(ISTAT, 2015). Another study confirmed the decreasing trend
observed over the last five decades in men and over the last two
decades in women (Gallus et al., 2013). However, no significant
decrease in terms of smoking prevalence has been observed in
men or women between 2007 and 2014. This likely reflects the
lack of adoption of effective and relevant additional antismoking
measures after the successful ban introduced in 2005 (Joossens &
Raw, 2014) and smoking prevalence has levelled off over the last
few years (Osservatorio Fumo, Droga e Alcol, 2016). In 2005 the
Italian government banned smoking in all indoor public places,
including offices, cafes, restaurants (except for a few with separate
and regulated smoking areas), airports, and railway stations. Italy
was the first large country in Europe to introduce a comprehensive
smoking ban, which resulted in a further acceleration of the
decreasing trend of smoking prevalence in both sexes (Gallus et
al., 2006; ISTAT, 2015; Tramacere et al., 2009). In February 2016,
the Italian government established new legislation regarding
tobacco smoking. New anti-smoking laws have imposed large
fines for several offences and make it illegal to smoke in a car car-
rying children or pregnant women. The laws require cigarette
packs to carry health warnings about the effects of smoking.
Smoking is also prohibited outdoors near schools and hospitals.
Tobacconists caught selling cigarettes to minors risk heavy fines
and losing their license. Throwing cigarette butts on the pavement
could cost an offender up to 300 Euros (OSSFAD, 2016).
However, after the positive initial effects of the law of 2005, the
prevalence of smokers in Italy has not decreased further and has
instead remained static (OSSFAD, 2018). 
Smoking traditional cigarettes is one of the largest risk factors
for premature mortality from non-communicable diseases in the
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general population (Stringhini et al., 2017). Tobacco use is the
greatest threat to public health worldwide, killing more than seven
million people each year (WHO, 2017). Cigarette smoking is the
single most preventable cause of death and disease. Smoking-relat-
ed death is principally caused by lung and other cancers, ischemic
heart disease and Chronic Obstructive Pulmonary Disease (COPD)
(WHO, 2012; Doll, Peto, Boreham, & Sutherland, 2004). The risk
of serious disease has been shown to diminish rapidly after smok-
ing cessation – ‘quitting’ – and permanent abstinence markedly
reduces the risk of lung cancer and other cancers, ischemic heart
disease and COPD. Considering that the main types of these non-
communicable diseases are Cardiovascular Diseases (CVDs), can-
cers and chronic respiratory diseases, helping traditional cigarette
smokers quit and remain abstinent is one of the most effective
ways we can improve the public health of Italy, UK and the rest of
the world. The associations between traditional cigarette smoking
and hazards to physical health are described below. Cigarette
smoking is probably the most complex and the least understood
amongst the risk factors for CVDs. Cigarette smoke contains sev-
eral thousand chemicals, though there isn’t concordance about the
exact number of chemicals. Two studies report traditional
cigarettes contain ≈4000 different chemicals with sizes ranging
from atoms to particulate matter (Burns, 1991; Zemann, 2011) and
other two more recent papers demonstrate tobacco smoke contains
more than 7000 chemicals (Perfetti & Rodgman, 2013; Tobacco
Atlas, 2015). Individual smoking behavior, intensity of smoking
and the brand of cigarettes smoked further modulate the amount,
number, and type of chemicals in tobacco smoke to which an indi-
vidual is exposed (Conrad, 2011). Importantly, it is likely that it is
not just a single compound or a compound class, such as oxidants,
but rather a highly complex and changing mixture of compounds
that is responsible for disease initiation, progression, and cardio-
vascular outcome. The interplay of these compounds with the indi-
vidual’s genetic background and the environment defines the
onset, location, and pace of CVDs. For the past few decades, it has
been clear that smoking is an important (and modifiable) risk fac-
tor for CVDs; according to WHO data, smoking is responsible for
10% of all CVD cases (WHO, 2012). However, for a long time it
remained unclear how smoking causes CVDs. In 1993, Celermajer
et al. published a study showing that smoking reduces Flow-
Mediated Dilatation (FMD) in systemic arteries in healthy young
adults. Smoking not only plays a strong role in CVD initiation, but
also significantly contributes to and causes disease progression and
fatal cardiovascular outcomes. Current data clearly show that sec-
ond-hand smoking can also trigger life-threatening conditions.
Management and prevention of CVDs is a public health priority,
and a simple intervention such as smoking cessation could lead to
reduced prevalence of cardiovascular risk factors and, therefore,
CVD itself.
There is a clear link between smoking initiation and cancer in
later life. Smoking causes more than 48% of deaths from the 12
types of cancer caused by smoking. Smoking causes more than
80% of lung cancer deaths as well as 77% of larynx cancer deaths
(Siegel et al., 2015). Approximately 168,000 people in the United
States are estimated to die of cancer due to smoking each year.
Continued progress in reducing cancer mortality will require more
comprehensive tobacco control, including targeted cessation sup-
port (de Marco et al., 2004; Siegel et al., 2015). In Europe, the
incidence of lung cancer ranges from eight to 62 per 100,000 per-
sons, while prevalence ranges from 26 to 242 per 100,000 persons
(Jimenez-Ruiz et al., 2011). In Europe, death rates from lung can-
cer increased by 58% between 1960 and 1988, but they declined by
14% in 1998, mainly due to the decreased incidence and mortality
in males (Ezzati & Lopez, 2003). The risk of developing lung can-
cer seems to be affected by the duration of smoking and the num-
ber of cigarettes (or cigars, or pipes) smoked daily (La Vecchia
Franceschi, & Levi, 2003). The Relative Risk (RR) ratio between
the occurrence of lung cancer amongst smokers and nonsmokers is
15 overall and 25 for heavy smokers (Doll et al., 2004). Reducing
the intake of traditional cigarettes smoked per day may support a
harm reduction approach but the US Cancer Prevention Study II
has shown that the number of years of tobacco smoking is far more
critical in predicting lung cancer risk than the number of cigarettes
smoked daily (Alberg & Samet, 2003). The age of starting smok-
ing increases lung cancer risk (Flanders, Lally, Zhu, Henley, &
Thun, 2003); hence, promoting interventions to avoid smoking ini-
tiation (typically during the adolescence) are important.
Smoking is also the main cause of many respiratory diseases
(CDC, 2004). COPD is predicted to become the third leading cause
of death in 2030 (WHO, 2008). Cigarette smoking is the most
important risk factor for COPD and it can also promote the onset
of exacerbations (Wedzicha & Donaldson, 2003). Data collected in
European countries show that self-reported diagnosis of chronic
bronchitis/emphysema (Viegi et al., 1999) or spirometry signs of
airflow obstruction (Lundback et al., 2003) are more frequent in
smokers than nonsmokers. The risk of developing COPD may be
increased not only by the average daily number of cigarettes
smoked but even more by cumulative pack-years (Viegi et al.,
1999). Moreover, a study has shown that smokers with COPD have
higher tobacco consumption, higher CO levels in exhaled air and
higher dependence on nicotine than healthy smokers (Lundback et
al., 2003). However, despite COPD being considered as a smok-
ing-related lung disorder, not all traditional cigarette smokers
develop this disease. Faner et al. (2014) showed that some smokers
may develop irreversible lung obstruction, which is linked with
their epigenetic and genetic background (DeMeo et al., 2004) but
smoking cessation plays a central role in COPD avoidance.
Cigarette smoking is also a risk factor for male and female sexual
and reproductive dysfunctions. In particular, it is a risk factor for
the onset of erectile dysfunction and traditional cigarettes contain
elements that exert a direct harmful effect on male and female
germ cells and embryos (Zenzes, 2000). Tobacco use amongst
women during their reproductive years is especially dangerous
because of the potential for multi-generational harm. Smoking is
associated with poorer pregnancy outcomes including infertility,
ectopic pregnancy, increased rates of spontaneous abortion and
still births. Smoking contributes to preterm birth, low birth weight,
increased rates of infant chronic lung disease, wheezing, and an
increased risk for Sudden Infant Death Syndrome (DiFranza &
Lew, 1996).
Smoking cessation treatments 
Offering help to quit tobacco use in people dependent on
tobacco is one of the six proven policies identified by the WHO
Framework Convention on Tobacco Control (FCTC) to address the
tobacco epidemic (WHO 2003; CDC, 2004). Key barriers to devel-
oping national smoking cessation policies and tobacco-control
supportive programmes are: inadequate training and lack of moti-
vation amongst healthcare providers to undertake and deliver
smoking cessation activities; lack of resources and government
funding; unavailability and inaccessibility of pharmacotherapy
products; the absence of mechanisms for financing or subsidising
pharmacotherapy products by insurance companies; lack of coor-
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dination between various sectors involved in providing smoking
cessation interventions; and, more importantly, the lack of integra-
tion of smoking cessation interventions into an overall policy on
tobacco control. The FCTC came into force on February 27, 2005
and requires Parties to implement evidence-based measures to
reduce tobacco use and exposure to tobacco smoke (WHO, 2013).
Article 14 of the FCTC requires Parties to take effective measures
to promote cessation and adequately treat tobacco dependence.
Guidelines for the implementation of Article 14 recommend estab-
lishing specialized tobacco dependence treatment services, making
medications widely available and considering emerging research
evidence and novel approaches to cessation. The 2008 US Guide
to Quitting Smoking recommends that, except for groups with con-
traindications or for whom smoking cessation drugs have uncertain
efficacy (e.g., users of smokeless tobacco, light smokers, pregnant
women, nursing women, and teenagers), clinicians should encour-
age all smokers intending to quit smoking to take smoking cessa-
tion medications combined with smoking cessation advice (2008
PHS Guideline Update Panel, Liaisons, and Staff, 2008)
There is evidence regarding the efficacy of the drugs used in
smoking cessation (Bauld, Bell, McCullough, Richardson, &
Greaves, 2010; Cahill, Stevens, Perera, & Lancaster, 2013). The
drugs are most effective when used incombination with behavioral
therapies and support. Cognitive and behavioral interventions,
such as motivational interviewing and relapse prevention, are an
essential adjunct for the efficacy of these treatments (Bauld et al.,
2010; Cahill et al., 2013). In the general population there are three
principal approved drug therapies, according to US International
Guidelines: Nicotine Replacement Therapy (NRT), varenicline,
and bupropion (2008 PHS Guideline Update Panel, Liaisons, and
Staff,, 2008).
Nicotine replacement therapy
NRT has an established evidence base in the general popula-
tion. Multiple formulations are available – gum, lozenges, oral
strips, sublingual tablets, inhalers, mouth and nasal sprays, and
transdermal patches (16- or 24-hours release). All have comparable
efficacy. These different formulations allow for better tailoring to
individual requirements including the use of combinations if
required. For example, a patient may be prescribed a transdermal
nicotine patch and additionally use a nicotine inhaler to supple-
ment blood nicotine concentrations at times of particular craving
or risk of relapse (Stead et al., 2012). The OR of abstinence for any
form of NRT compared with placebo is 1.84 (Cahil et al., 2013).
Combined NRT formulations have been shown to result in higher
abstinence rates than single NRT. The OR of abstinence for com-
bination NRT compared with single NRT products is 1.43 (Cahil et
al., 2013).
Varenicline
Varenicline has comparable efficacy with combination NRT
but has superior efficacy to nicotine replacement monotherapy. It
is therefore recommended as an equal first-line drug for smoking
cessation. Varenicline acts as a partial agonist at central nicotinic
acetylcholinergic receptors, which are important in mediating the
reinforcement associated with tobacco smoking. During treatment,
drug binding partially activates these receptors thereby reducing
withdrawal symptoms and cravings. If the patient lapses and
smokes, varenicline reduces the access of nicotine to the receptors.
By limiting nicotine binding, varenicline reduces its rewarding
effect. It is recommended that varenicline is started a week or two
before the patient quits smoking. This is because a continuous peri-
od of dosing is required before sufficient receptors are occupied
and optimal drug efficacy is achieved. The recommended dosage
is one mg twice daily (for 12 weeks) following a one week up-titra-
tion (2008 PHS Guideline Update Panel, Liaisons, and Staff,
2008). In the most recent Cochrane review, Cahill, Lindson-
Hawley, & Thomas, (2016) reported that the OR of continuous
abstinence for varenicline compared with placebo was 2.24;
varenicline was more effective when compared with bupropion
(OR 1.39) and single-product NRT (OR 1.25), and was similarly
effective compared with combination NRT. Varenicline is princi-
pally eliminated by the kidneys so reduced doses (or alternative
treatments) are recommended for patients with renal impairment.
Common adverse effects include nausea, headache and insomnia.
Bupropion
Bupropion was originally developed as an antidepressant. It
has dopaminergic and adrenergic actions and is an antagonist at the
nicotinic acetylcholinergic receptor; however, its precise mode of
action in smoking cessation is uncertain. It has equivalent efficacy
to nicotine replacement monotherapy but is less effective than
varenicline and is therefore considered a second-line option (2008
PHS Guideline Update Panel, Liaisons, and Staff, 2008). The rec-
ommended dosage of bupropion is 150 mg twice daily. Several
meta-analyses have confirmed the efficacy of bupropion (Hughes,
Stead, & Lancaster 2007; 2008 PHS Guideline Update Panel,
Liaisons, and Staff, 2008). In a network meta-analysis by Cahill et
al. (2013), the OR of abstinence for bupropion compared with
placebo was 1.82. Bupropion was of similar efficacy to single
product NRT (RR 0.99) and less effective for quitting compared
with varenicline and combination NRT. Bupropion has been shown
to decrease nicotine/tobacco withdrawal symptoms and cigarette
cravings (Mooney & Sofuoglu, 2006). Bupropion is contraindicat-
ed in patients with a history of seizures. Common adverse effects
include difficulty concentrating, insomnia and nightmares.
Bupropion undergoes significant hepatic CYP 2B6 metabolism to
an active metabolite (hydroxybupropion), which is later excreted
renally. Dose reduction is necessary in patients with hepatic or
renal disease. There are potential interactions with other drugs
metabolized by this system including antipsychotics and selective
serotonin reuptake inhibitors.
Tobacco harm reduction
The history of Tobacco Harm Reduction (THR) may be traced
back to at least 1974, with the publication of a special article in the
Lancet by British tobacco addiction research expert Michael A.H.
Russell (1974). In essence, harm reduction as part of a tobacco
control strategy involves trying to separate the risk associated with
inhaling smoke from that of taking nicotine. As Russell noted 30
years ago, “There is little doubt that if it were not for the nico-
tine…people would be little more inclined to smoke than they are
to blow bubbles or light sparklers” (Russell, 1974). More recently,
the National Institute for Health and Care Excellence (NICE) in
the UK has described THR as reducing the diseases and deaths
caused by smoking traditional cigarettes (NICE, 2011). NICE pro-
duced the world’s first formal guidelines on THR between 2011
and 2013. These guidelines address reducing harm from smoking
traditional cigarettes in order to help smokers, particularly those
who are highly dependent on nicotine, and may not be able (or do
not want) to stop smoking in one step; may want to stop smoking,
without necessarily giving up nicotine; and may not be ready to
stop smoking, but want to reduce the amount that they smoke










(NICE, 2013). Despite the NICE harm reduction guidelines,
approved smoking cessation treatment in the UK and other coun-
tries normally requires nicotine addicted smokers to abstain from
tobacco and nicotine entirely. Many smokers are unable – or at
least unwilling – to achieve this goal, and so they continue smok-
ing in the face of impending adverse health consequences. In
effect, established approaches to smoking cessation present smok-
ers with just two alternatives: stop smoking or suffer the harmful
effects of continuing smoking. However, THR arguably provides a
third choice for smokers. It involves the use of alternative sources
of nicotine as a replacement for smoking. E-cigarettes as a product
category can fit within a THR paradigm. They can deliver nicotine
without the combustion products that are responsible for nearly all
of smoking’s damaging effects. These products and key available
evidence about their use is outlined in the next sections of this
chapter.
The E-cigarettes
E-cigarettes are a part of a series of emerging products often
referred to as Alternative Nicotine Delivery Systems (ANDS) or
Electronic Nicotine Delivery Systems (ENDS). The term ENDS
was created by the WHO’s Study Group on Tobacco Regulation in
2009 to classify a collection of battery-powered devices that pro-
vide nicotine flavourings and other additives to the user in aerosol
form. A first version of an e-cigarette was patented as early as 1965
in the USA by Gilbert (Gilbert, 1965). The Gilbert e-cigarette
resembled a traditional cigarette but instead of burnt tobacco, it
allowed the user to draw warm flavoured vapour into the mouth or
lungs. A cartridge held a chemical solution and an insulated tube or
light bulb powered by a battery provided a heating element to heat
the solution. However, despite this innovative idea, Gilbert was
never able to bring this product successfully to market. Some years
later, in 1986, the ‘Favor’ cigarette was developed as a non-com-
bustible nicotine-containing product that also resembled a cigarette
in appearance (Ling & Glantz, 2005). The device was made of a
plastic tube containing a paper soaked with nicotine in order to
simulate the traditional cigarette effect without vapour creation.
The Food and Drug Administration (FDA) in the USA deemed this
type of device to be a nicotine delivery system and as consequence
classified Favor as a drug and banned it (Sleight, 2016). Following
these very early designs, the modern e-cigarette was developed in
2003 by a Chinese pharmacist, Hon Lik. He created an electronic
atomizing cigarette for smoking cessation after his father (a smok-
er) died of lung cancer. This e-cigarette was composed of a battery-
operated device designed to vaporize a liquid solution of propylene
glycol and vegetable glycerine in which nicotine was dissolved.
No tobacco was used in the device. Puffing activated a battery-
operated heating element in the atomizer and the liquid in the car-
tridge was vaporized as a plume of a dense mist and inhaled (Hon,
2003). This e-cigarette prototype showed promise, and as a result
in 2004 it was introduced on the Chinese market under the compa-
ny name Ruyan. From there many other companies began to devel-
op similar devices building on this initial prototype. The technolo-
gy and range of products rapidly evolved and the market grew con-
siderably from 2010 onwards. These products have now spread
rapidly across Europe, the USA and a number of other areas and
countries (Sanford, Goebel, & Lynne, 2014).
E-cigarette market and types
As of 2014, it was estimated that over 460 e-cigarette brands
were available on the global market (Zhu et al., 2014). However,
despite the potential product differences, some characteristics of e-
cigarettes appear to be consistent across products. These include: a
cartridge containing propylene glycol or glycerine mixed with dif-
ferent nicotine concentrations and a battery powered heating com-
ponent which transforms the liquid substance into an aerosol form
when air is drawn through the device (Cobb, Byron, Abrams, &
Shields, 2010). E-cigarettes are also sold as either disposable or
reusable, refillable products. E-cigarette devices vary from first
generation, second generation, and third and fourth generation
products.
First-generation e-cigarettes appear similar to traditional
cigarettes, usually with a white body made of plastic and a tan
mouthpiece (other first-generation e-cigarettes were slightly longer
or narrower than a traditional cigarette and were black or
coloured). These devices are described as “cigalikes.” First gener-
ation models included a cartridge designed for the part of the
device that holds the e-liquid, which is either prefilled with the liq-
uid or ready to be filled. The user then connects the cartridge to the
heating element and atomizer that are themselves connected to the
battery, and the “cigalike” is ready for use (Zhu et al., 2014).
Second-generation e-cigarettes include devices that resemble
fountain pens, are large and cylindrical, and are often described as
e-cigarettes with “tank systems” in consideration of the transparent
reservoir that holds larger amounts of e-liquid (about two or three
ml) than previous first generation “cigalike” models.
Third generation devices are a diverse product category, and
they appear totally different from traditional cigarettes in their
appearance, principally because many are square or rectangular
and customizable by changing batteries and atomizers. Since the
beginning of the availability of e-cigarettes’ component elements,
users have been modifying their own e-cigarettes by building their
own customized e-cigarettes, which are called “mods.” Users can
adjust the battery voltage and combine the e-liquid, choosing dif-
ferent flavours and nicotine levels (Richtel, 2014; Lee & Kim,
2015).
Fourth generation devices are the most advanced and powerful
and differ from third-generation e-cigarettes in the following small
details: they enable control over the temperature of the heating coil
and can be used at much higher power levels (e.g., >200 W) com-
pared with most earlier e-cigarettes (Strongin, 2019).
E-cigarette devices have evolved substantially over time, from
early-generation cigalike e-cigarettes to more advanced modifiable
tank-style versions. One of the latest products to be introduced on
the market, initially in the USA, is the JUUL e-cigarette (Truth
Initiative, 2018). JUUL is a non-modifiable compacted closed sys-
tem e-cigarette and represents one of a newer generation of pod
devices.
JUUL has two basic components: the device, which includes
the battery and temperature regulation system, and the prefilled e-
liquid cartridge, called a ‘pod’, that comes in a variety of flavours
(tobacco, mango, mint, and others). The original JUUL device
pods contained 0.7 mL of e-liquid with 5% nicotine by weight,
although lower strength nicotine options are now on the market,
particularly in Europe.
The JUUL pods also serve as the mouthpiece for the product.
JUUL is rechargeable by a USB port and is rectangular and small
in size, fashioned to look like a computer flash drive (Kee, 2018).
The characteristics that make JUUL different from its predecessors
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include its design (called the ‘iPhone of e-cigarettes’) (Radding,
2015), its high levels of nicotine (0.7 mL or 59 mg/mL per pod)
and the use of a specific e-liquid formula, JUUL salts, based on the
nicotine salts found in leaf-based tobacco rather than free-based
nicotine. JUUL provides a nicotine concentration comparable with
a traditional cigarette, with the nicotine peaking in about five min-
utes, and delivers nicotine 1.25–2.7 times faster than competing e-
cigarettes on the market (Brown & Xing, 2015; JUUL, 2018;
Lawler, 2018).
Existing evidence on e-cigarette harms and benefits
Although e-cigarettes have only become widely used in the last
few years, research evidence on these devices has been growing
rapidly. This evidence is not always consistent and sometimes con-
tradictory, but there is a growing consensus that these products are
significantly less harmful than traditional cigarettes (Farsalinos &
Polosa 2014). That said, important research questions remain
regarding any potential harms from use and also the potential ben-
efits of use. These questions include, for example, whether these
products are effective aids for smoking cessation, promote uptake
by nontobacco users, sustain nicotine dependency via dual use,
slow intentions to quit in dual users, or encourage relapse to
cigarette use amongst former smokers (Glasser et al., 2017). E-
cigarette use is a complex and dynamically evolving behaviour. To
advance knowledge of the impact of e-cigarettes use on smoking
status, it will be necessary to conduct prospective studies consider-
ing relevant descriptors of vaping behaviour such as frequency of
use (e.g. focusing on daily users, and not just on those who are
experimenting), reasons for using e-cigarettes (e.g. to quit smoking
vs. out of curiosity), and product design (e.g. closed vs. open sys-
tems, nicotine containing vs non-nicotine containing products,
etc.). Reasons for vaping, the type of device and e-liquid, frequen-
cy of use, and the accompanying sensory and craving-control
experiences may have some impact on smoking behaviours
(Polosa et al., 2017). E-cigarettes have ingredients that are not
inert and are likely to have some potential health risks. While tra-
ditional cigarette combustion generates toxic substances correlated
with cancers, respiratory disorders and CVDs, e-cigarettes usage
delivers potentially toxic substances involving fine particulate
matter, metals that are known to probably determine adverse health
effects related to cancers, respiratory disorders and CVDs.
E-cigarette-related toxicants and carcinogens: A number of
studies have tried to assess the RRs of e-cigarette use compared
with tobacco smoking, in particular, the extent to which there is
any reduction in exposure to harmful toxicants as compared with
smoking traditional cigarettes. For example, in one study, a
research group provided 40 smokers with e-cigarettes in a choice
of eight flavours with 12 mg or 24 mg of nicotine. The researchers
collected urinary cotinine, the tobacco-specific carcinogen 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and eight
volatile organic compounds at BL visit and a four week follow-up
visit. They observed that CO (p<0.001), NNAL (p<0.01), and
metabolites of benzene (p<0.01) and acrylonitrile (p=0.001)
decreased significantly in smokers who switched to e-cigarettes
(Pulvers et al., 2016). Another recent study (Shahab et al., 2017)
compared, in 37 participants of traditional cigarette-only smokers,
and in 72 smokers and 72 ex-smokers with long-term e-cigarette
use or with use of NRT, the exposure to nicotine, tobacco-related
carcinogens and toxicants. Urine and saliva samples were collected
and there were no differences in salivary or urinary biomarkers of
nicotine intake after controlling for confounders. The study found
lower carcinogen and toxicant levels in participants who had
switched completely from smoking to either exclusively e-
cigarettes or NRT use. However, both of the studies, conducted by
Pulvers et al. and Shahab et al., used samples too small to assess
the potential association of different types of e-cigarettes, did not
assess indirect exposure and were limited by the number of
biomarkers available. A large study used data from 5,105 of the
U.S. adults participating in the Population Assessment of Tobacco
and Health (PATH) study and compared exposure to toxicants
amongst e-cigarettes users, non-smokers and smokers. This study
examined urine samples for key biomarkers of exposure to harmful
chemicals, Tobacco-Specific Nitrosamines (TSNAs), metals,
Polycyclic Aromatic Hydrocarbons (PAHs), and volatile organic
compounds (VOCs), and suggested possible benefits for smokers
who totally switched to e-cigarettes. Exclusive users of e-cigarettes
were exposed to more toxicants than people who did not use any
form of traditional cigarette, but at significantly lower levels than
smokers (Goniewicz et al., 2018). 
E-cigarette use and cancer risk
The cancer risk related to e-cigarette usage would be expected
to be less than traditional cigarettes based on the fact that e-
cigarettes include nicotine but not many of the other toxicants in
traditional combusted cigarettes. On this basis their use should
result in a reduced burden of carcinogens compared with smoking
(Chen et al., 2017; Stephens, 2018).
A small number of studies to date have focused on e-cigarette
users and cancer. For example, in a study conducted by Franco,
Trapasso, Puzzo, and Allegra (2016), oral cells were collected by
scraping the oral mucosa from a population of 65 participants from
three groups: traditional cigarette smokers (n=23); e-cigarette
users (n=22); and non-smokers or users of traditional cigarettes
and e-cigarettes (n=20). Their findings showed that compared with
non-smokers of traditional cigarettes and non-users of e-cigarettes,
the mean number of micronucleated cells/1,000 cells and the mea-
sure of total micronuclei/1,000 cells was respectively 160% and
633% higher in traditional cigarette smokers and 21% and 133%
higher in e-cigarette users. This study, despite not presenting any
evidence on the reliability of the micronucleus assay, nor reporting
all important p-values, or several potential confounding factors
(e.g. age, or age at smoke initiation), showed that the average
micronuclei burden was high in e-cigarette users compared with
never smokers, and was higher in traditional cigarette smokers
compared with e-cigarette users and never smokers. A further
study assessing RRs compared with smoking was conducted by
Manzoli et al. (2017). They enrolled 932 participants at BL assess-
ment with the following sample sizes at the end of the 24-month
follow-up: 363 smokers of only traditional cigarettes throughout
follow-up, 97 users of only e-cigarettes throughout follow-up, and
37 dual users of both traditional and e-cigarettes. This study report-
ed the definition “any cancer” as one of the possible Serious
Adverse Events (SAEs) in participants with this distribution: 0.8%
(3/363) in traditional cigarettes users, 2.1% (2/97) in e-cigarettes
users and 0% (0/37) in dual users. The risk ratios calculated from
these data, using traditional cigarettes as the referent category,
were 2.49 (95% CI 0.42-14.72) for e-cigarettes only and 0 (95% CI
not estimable) for dual use. Considering that all participants were
previous traditional cigarette users, the findings did not provide
any indication of elevated cancer risk from sole use of e-cigarettes.
However, the study did have limitations including: the absence of
consideration of traditional cigarette smoking history, a small sam-
ple size to evaluate the endpoint of cancer, and self-reported cancer










data. Studies in humans focusing on cancer and e-cigarette use are
relatively few in number, and to date there are no epidemiological
studies on the possible association between e-cigarette use and
cancer in humans. This makes it difficult to draw definitive conclu-
sions about any association between e-cigarette use and risk of
cancer in human populations. However, a joint statement on e-
cigarettes by Public Health England and other UK public health
organisations (PHE, 2016) developed a shared agreement docu-
ment stating that e-cigarettes are significantly less harmful than
smoking. A recent study conducted by Stephens (2018) measured
emissions from cigarettes and e-cigarettes, calculating lifetime
cancer risk using daily consumption estimates, and calculated that
e-cigarette cancer potencies were largely found to be only a small
fraction of those of smoking (0.4%).
A different body of research has focused on e-cigarettes’
effects on users of traditional cigarettes with or without pre-exist-
ing respiratory conditions such as COPD or asthma. These studies
in humans examine the effect of switching to e-cigarettes (single or
dual use), examine health effects of e-cigarettes compared with tra-
ditional cigarette usage, and overall suggest that smokers with pre-
existing respiratory conditions such as asthma and COPD may
experience some benefits from switching to e-cigarettes
(Campagna et al., 2016; Cibella et al., 2016; Polosa et al., 2014 a,
b; Polosa et al., 2016 a, b). Our research group in Italy has con-
tributed to this literature on respiratory health and e-cigarettes. In
a one-year RCT of healthy smokers who abstained from cigarette
smoking and switched to e-cigarette use, we observed improve-
ments in their exhaled breath measurements, including fractional
nitric oxide concentration in exhaled breath (FeNO) and exhaled
carbon monoxide (eCO) (Campagna et al., 2016). A 24-month
prospective study (Polosa et al., 2016) demonstrated improved res-
piratory symptoms and lung function in 16 former smokers who
switched to e-cigarettes, suggesting that e-cigarette use could
potentially contribute to reversing the harm from combustible
tobacco in smokers with asthma. Polosa et al. (2017) conducted a
study with young-adult never-smoking, daily e-cigarette users who
were followed up for at least 3½ years by our research group. No
worsening in spirometric indices (i.e. lung function), no develop-
ment of respiratory symptoms, no changes in markers of lung
inflammation in exhaled air, and no signs of early lung damage on
High Resolution Computed Tomography (HRCT) were detected.
However, a limitation of these studies is that they were conducted
in a small number of smokers selected retrospectively from the
same region and primarily from a single study research group,
which limits generalizability of the results. Different findings
come from a high-quality RCT with large sample size, where
Cravo et al. (2016) reported no difference in lung function in
smokers who switched to e-cigarettes. In this study smokers with
respiratory conditions were excluded and two cohorts of smokers
were randomised to either change to e-cigarettes with nicotine or
continue smoking traditional cigarettes. The authors reported no
significant positive or negative changes in pulmonary function
tests after 12 weeks between the two groups (Cravo et al., 2016).
Several recent studies have evaluated acute cardiovascular effects
such as modifications in Blood Pressure (BP) levels and Heart
Rate (HR) following e-cigarette use. Studies investigated modifi-
cations in BP levels after e-cigarette use (Cooke, Pokhrel,
Dowling, Fogt, & Rickards, 2015; Farsalinos, Spyrou,
Tsimopoulou, Stefopoulos, Romagna, & Voudris, 2014; Fogt,
Levi, Rickards, Stelly, & Cooke, 2016; Moheimani et al., 2017;
Szołtysek-Bołdys et al., 2014; Yan & D’Ruiz, 2015). These studies
had some inconsistent results, with the majority finding weak pos-
itive increases or no modifications and harms using e-cigarettes.
Previous studies, using first and second generation e-cigarettes,
found no changes in HR following e-cigarette use (Farsalinos et
al., 2014; Szołtysek-Bołdys et al., 2014; Vansickel, Cobb, Weaver,
& Eissenberg, 2010) but these were conducted with devices char-
acterized by slight or no increase in blood nicotine levels. In one
prospective study, using first and second generation e-cigarettes
and conducted by our team in Italy, systolic BP was significantly
reduced at week 52 compared with BL (132.4 +/- 12.0 vs. 141.2 +/-
10.5 mmHg, p<0.00) amongst participants who had reduced smok-
ing (>50% reduction) and in those who had quit smoking with the
use of e-cigarettes. These findings suggest that e-cigarette use does
not elevate BP (Farsalinos et al., 2016). This study did not find any
changes in BP when assessing all participants, because the vast
majority initially had normal BP and no change in this parameter
was expected to occur within the 12-month duration of the survey.
The interest was directed towards the population with an initially
high BP (high-normal or higher, as defined by the European
Society of Cardiology). The reduction in BP was evident even after
adjusting for confounders such as age, gender and weight gain.
However, these early studies may not reflect the effects of newer
devices. Some more recent research using third generation devices,
which increase blood nicotine levels, has identified some increase
in HR just after e-cigarette use (Cooke et al., 2015; Spindle et al.,
2016; St. Helen, Dempsey, Havel, Jacob III, P., & Benowitz,
2017). A key factor to consider when drawing any conclusions
about potential health risks from e-cigarettes is the extent to which
studies directly compare vaping with tobacco smoking. Those
studies that have aimed to directly compare the two have fairly
consistently found reduced levels of harm if participants switch
completely to vaping from smoking. Looking across the body of
literature, there is convincing evidence that vaping amongst ex-
smokers reduces exposure to toxicants that are carcinogenic and
may increase the risk of cancer. In addition, there is now good evi-
dence that risks to both cardiovascular (Yan & D’Ruiz, 2015;
D’Ruiz, O’Connell, Graff, & Yan, 2017) and respiratory health
(Polosa et al., 2014a,b; 2016b,c) are reduced when smokers switch
from using combustible tobacco to vaping.
E-cigarette use, craving and smoking cessation
Smokers with considerable histories of cigarette usage report
using e-cigarettes to alleviate nicotine withdrawal generated by
smoking cessation or to satisfy cravings for these traditional
cigarettes (Etter & Bullen, 2014). An RCT (Adriaens, Van Gucht,
Declerck, & Baeyens, 2014) on smoking behaviour and use e-
cigarettes in 48 traditional cigarettes smokers randomised partici-
pants into two e-cigarette groups and one control group.
One of the researchers’ objectives was to assess whether e-
cigarettes decreased craving in the short term, and during the lab-
oratory studies in the first two-month period of the study,
researchers assessed craving and found that e-cigarettes proved to
be just as effective in suppressing the craving for smoking as tra-
ditional tobacco cigarettes. Dawkins and Corcoran (2014) enrolled
14 experienced vapers and asked them to abstain overnight from
their traditional cigarettes. In the morning, they were presented
with a first-generation e-cigarette with 18 mg/mL nicotine, from
which they were invited to take 10 puffs. As a result, the nicotine
craving and urge to smoke were significantly reduced in these par-
ticipants. In a second study, Dawkins, Munafo, Christoforou,
Olumegbon, and Soar, (2016) presented 63 abstinent smokers who
were not current e-cigarette users with either a red or a white first
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generation e-cigarette containing 18 mg/mL of nicotine in the form
of “tobacco” flavored e-liquid after a 10-hour abstinence period.
Their results suggest that the visual appearance of an e-cigarette
has an effect on cigarette craving reduction. These researchers
found that the more the e-cigarette resembled a traditional
cigarette, the stronger the craving reduction. Another study
focused on e-cigarettes’ flavour (Goldenson et al., 2016) and
showed that nicotine-free and nicotine-containing e-cigarettes pro-
duced greater appeal when containing sweet flavours than when
containing non-sweet flavours or no flavour.
Smoking is a difficult addiction to break and many smokers
persist in tobacco use for numerous years, typically cycling
through multiple periods of remission and relapse (Caponnetto,
Keller, Bruno, & Polosa, 2013; Caponnetto, Russo, et al., 2013).
Yet, while complete cessation of any nicotine use may be the most
desirable final outcome, substitution of traditional cigarettes with
alternative non-combusted forms of nicotine delivery, such as e-
cigarettes, is now a relatively new option available to smokers.
Surveys of e-cigarette users have examined reasons for use and,
overall, these suggest that users report using them to help quit
smoking, to reduce cigarette consumption, to relieve tobacco with-
drawal symptoms, and to continue some of the behavioural aspects
of smoking with perceived reduced risks to (Etter, 2010).
The first RCT examining the impact of e-cigarettes on smok-
ing behaviour was conducted by the research team at the Centro
per la Prevenzione e Cura del Tabagismo-University of Catania
(CPCT), Italy, led by Professor Riccardo Polosa and including the
PhD candidate. This study found that smokers not immediately
willing to quit who used e-cigarettes substantially decreased daily
cigarette consumption without significant side effects (Caponnetto,
Campagna, et al., 2013). The trial involved 300 smokers without
mental health conditions recruited from advertisements in a local
newspaper in Catania. This double blind RCT examined the effects
of using a 7.2 mg nicotine e-cigarette, hereafter referred to as
Group A; 7.2 mg for six weeks, then transition to 5.4 mg nicotine
e-cigarettes, hereafter referred to as Group B; and nicotine-free e-
cigarettes, hereafter referred to as Group C, on smoking reduc-
tion/cessation and adverse effects. The primary outcome of the
study was >50% reduction in Cigarettes Per Day (CPD) at the 52-
week study visit from BL. The secondary outcome was sustained
smoking abstinence at the 52-week study visit.
The eligibility for study inclusion was adult smokers in good
health, age 18-70 years, using ≥10 factory-made CPD for at least
the past five years, not attempting/wishing to quit in the next 30
days. Exclusion criteria for the study were symptomatic CVD,
symptomatic respiratory disease, regular psychotropic medication
use, current or past history of alcohol abuse, use of smokeless
tobacco or NRT, pregnancy or breastfeeding. Participants were not
encouraged or given any motivation to cease smoking. Study par-
ticipants were instructed to use the product ad libitum throughout
the day, not to exceed a four cartridge/day maximum as recom-
mended by the manufacturer of the product. Participants attended
follow-up visits at 2, 4, 6, 8, 10, 12, 24, and 52 weeks. At each of
these visits, participant eCO levels were recorded, study diaries
were given to study personnel, and unused study products were
turned in. After 12 weeks, no additional cartridges were provided
to the participants. However, participants were told they could con-
tinue to use the e-cigarettes. Saliva cotinine levels were measured
at six and 12 weeks in participants who reported no smoking and
had an eCO ≤ seven ppm.
Loss to follow-up was 35/100 (35%) in Group A, 37/100
(37%) in Group B, and 45/100 (45%) in Group C. All patients were
analysed in the group to which they were first allocated with an
intention to treat philosophy. At week 52, 10/100 (10%) of those
allocated to Group A, 9/100 (9%) of those allocated to Group B
and 12/100 (12%) of those allocated to Group C had reduced their
CPD by ≥ 50%, p = 0.24. At week 52, 13/100 (13%) of those allo-
cated to Group A, 9/100 (9%) of those allocated to Group B and
4/100 (4%) of those allocated to Group C had achieved smoking
abstinence and had eCO concentrations of ≤ seven ppm, p=0.24.
Self-reported adverse effects amongst the remaining 183 partici-
pants of the study at 52 weeks included: throat irritation 37/183
(20.2%), mouth irritation 34/183 (18.6), dry cough 37/183
(20.2%), headache 5/183 (2.7%), shortness of breath 15/183
(8.1%). No SAEs (that is, major depression, abnormal behaviour
or any event requiring an unscheduled visit to the family practi-
tioner or hospitalization) occurred during the study.
The second RCT examining the impact of e-cigarette use on
smoking behaviour was conducted by the research team at the
National Institute for Health Innovation, University of Auckland
and Health New Zealand, Christchurch, led by Professor Chris
Bullen (Bullen et al., 2013). This research evaluated the quitting
efficacy, acceptability, and adverse effects of e-cigarettes, compar-
ing active (16 mg nicotine) e-cigarettes with nicotine patch and
placebo (0 mg nicotine) e-cigarettes. The trial was a three-arm par-
allel group RCT. A total of 657 smokers were randomised into one
of three groups: a group who used active e-cigarettes for 12 weeks
after quitting, a group using nicotine patches for 12 weeks, or a
group using placebo e-cigarettes for 12 weeks. Quit rates were
assessed at three and six months after the quit date. The primary
outcome was the proportion of smokers who maintained sustained
continuous abstinence from smoking for six months after their quit
day. Secondary outcomes were: continuous abstinence at one and
three months, seven-day point prevalence, proportion of partici-
pants who significantly reduced daily cigarette smoking by at least
25% in terms of numbers of CPD, and AEs.
Those eligibility for study inclusion were adult smokers in
good health, age ≥18 years, who had smoked at least 10 cigarettes
per day for the past year and were motivated to stop smoking.
Exclusion criteria for the study were: having had a heart attack,
stroke or severe angina in the previous two weeks; poorly con-
trolled asthma or other airway disease from self-report; poorly
controlled diabetes mellitus; severe allergies; poorly controlled
psychiatric disorders; or current drug dependence other than that
involving nicotine. Pregnant and breastfeeding women were
excluded.
At six months, the verified continuous abstinence was 7.3%
(21 of 289) with nicotine e-cigarettes, 5.8% (17 of 295) with nico-
tine patches, and 4.1% (three of 73) with no-nicotine e-cigarettes.
No significant difference between e-cigarette users compared with
nicotine patch users was found in six-month abstinence rates (RR
1.26, 95% CI = 0.68 to 2.34).
A significantly higher proportion of e-cigarettes users, com-
pared with nicotine patch users, achieved a 50% or more reduction
in traditional cigarette use (57% vs 41%; RR 1.41, 95% CI 1.20 to
1.67). The first group reduced traditional cigarette consumption by
an average of 9.7 (SE 0.4) CPD, compared with a reduction of 7.7
(SE 0.4) showed by nicotine patch users (p=0.002). The authors
noted no evidence of an association between AEs or SAEs and
products used in their study. There are also non-randomised studies
of e-cigarettes for smoking cessation and this literature is too
extensive to summarise those here.
Following these early studies, a large number of subsequent
studies have been published focusing on e-cigarettes for smoking
cessation. These have been summarized and assessed in a number
of systematic reviews; in fact, there are 22 systematic reviews of e-










cigarettes for smoking cessation published to date.
The most robust of these is the Cochrane review of e-cigarettes
for smoking cessation, first published in 2014 and subsequently
updated in 2016. In this Cochrane review of the effect of e-
cigarettes on smoking cessation, Hartmann-Boyce, McRobbie,
Bullen, Begh, Stead, and Hajek (2016) identified 24 studies: two
RCTs that followed participants for at
least six months (described in section 2.3.1 above) and 22
observational studies which followed participants for less than six
months or did not put people into treatment groups so could not
directly compare e-cigarettes with something else. The authors
also identified 15 ongoing trials. The two RCTs compared e-
cigarettes with and without nicotine and had a combined sample
size of 662 participants (Bullen et al., 2013; Caponnetto,
Campagna, et al., 2013). One trial included minimal telephone
support, one recruited smokers not intending to quit, and both used
early e-cigarette models with low nicotine content and poor battery
life. In the meta-analysis of the two trials, e-cigarettes had a higher
smoking cessation rate compared with placebo e-cigarettes. Nine
per cent of participants using an e-cigarette containing nicotine
successfully quit for at least six months compared with 4% of par-
ticipants using a placebo e-cigarette (RR 2.29, 95% CI 1.05 to
4.96). Also, in this review, none of the studies found that smokers
who used e-cigarettes short- to mid-term (for two years or less) had
an increased health risk compared with smokers who did not use e-
cigarettes.
Hartmann-Boyce et al. (2016) judged the RCTs to be at low
risk of bias, though they rated the overall quality of the evidence
as ‘low’ or ‘very low’, because of imprecision due to the small
number of trials. According to the Grading of Recommendations,
Assessment, Development and Evaluations (GRADE) system used
in Cochrane reviews, a ‘low’ grade means that further research is
very likely to have an important impact on the confidence in the
estimate of effect and is likely to change the estimate. A ‘very low’
grade means there is uncertainty about the estimate.
The WHO commissioned El Dib et al. (2017) to conduct a sys-
tematic review and meta-analysis of the effect of e-cigarettes on
traditional cigarette use amongst smokers. This research compared
e-cigarettes with nicotine with e-cigarettes without nicotine and
two independent reviewers, who also extracted data and assessed
the studies’ risk of bias, independently evaluated prospective
observational studies published up to December 2015. Three eligi-
ble randomised trials were considered, with 1,007 participants, but
the third randomised trial was excluded because the effect of e-
cigarettes versus no e-cigarettes couldn’t be compared for 24
weeks; hence, a total sample of 481 participants was considered.
These researchers also identified nine eligible cohort studies with
13,115 participants but concluded overall that there was still limit-
ed evidence about the effectiveness of e-cigarettes for smoking
cessation. These two systematic reviews considered a similar
group of studies and arrived at similar conclusions: that the avail-
able studies are few and that additional evidence is needed to pro-
vide a definitive conclusion. However, the reviews differed slight-
ly in their interpretation. The Hartmann-Boyce et al. (2016) sys-
tematic review found a statistically significant effect of nicotine e-
cigarettes compared with e-cigarettes without nicotine and consid-
ered this an important effect of e-cigarettes on quitting, and El Dib
et al. (2017), using the same studies, were more cautious in their
conclusions.
Kalkhoran and Glantz (2016) conducted a systematic review
and meta-analysis and identified 38 eligible studies about the
impact of e-cigarette use on smoking cessation amongst adult
smokers. In this systematic review and meta-analysis, the authors
included cohort studies, cross sectional studies, and randomised
and non-randomised clinical trials published up to December 2015
and concluded that e-cigarettes are associated with significantly
less quitting amongst smokers (Kalkhoran & Glantz, 2016).
Khoudigian et al. (2016) published a systematic review and
meta-analysis of RCTs and observational studies about smoking
cessation for at least 24 weeks after the start of e-cigarette adop-
tion. These authors observed that despite their findings, which sug-
gested that e-cigarettes with nicotine increased the proportion of
smokers who quit (RR of 2.02 (95% CI=0.97-4.21), this change
was not statistically significant in their meta-analysis.
Consequently, the authors concluded that several larger high-qual-
ity studies are needed to inform policy decisions.
In conclusion, the existing systematic reviews on e-cigarettes
for smoking cessation have inconsistent results. However, all iden-
tify the need for further research, in particular further RCTs.
Since the trials, observational studies and systematic reviews
mentioned above were conducted, there have been furthermore
recent studies on e-cigarettes for smoking cessation. In particular,
three recent population-based, cross sectional studies have been
conducted that identify promising smoking cessation rates, partic-
ularly amongst more frequent e-cigarette users (Giovenco &
Delnevo, 2018; Levy, Yuan, Luo, & Abrams, 2017; Zhu, Zhuang,
Wong, Cummins, & Tedeschi, 2017).
Firstly, Giovenco & Delnevo (2018) conducted a retrospective
cohort study by including smokers and former smokers who quit in
2010 or later. Amongst these participants daily e-cigarette users
and former smokers were 52%, daily e-cigarette users and never e-
cigarette users were 28%, [adjusted Prevalence Ratio (aPR) 3.15,
95% CI = 2.66, 3.73]. Compared with participants who never used
e-cigarettes (aPR 0.38, 95% CI = 0.32, 0.47), those who previously
used e-cigarettes but did not use them currently and those who
used them on only some days were less likely to be former smokers
(aPR 0.67, 95% CI = 0.61, 0.75).
In addition, Levy et al. (2017) retrospectively generated a
cohort of smokers who were using traditional cigarettes one year
prior to their survey. This research focused on the association
between e-cigarette use and having made a quit attempt in the past
year, and having been abstinent from traditional cigarettes for a
minimum of 12 weeks after a quit attempt. By using multiple logis-
tic regression analysis, their findings suggested that: quit attempt
in the past year was related to previous or current e-cigarettes
usage and that the probability of smoking cessation for 12 weeks
or more was significantly associated with e-cigarette use.
Finally, in terms of the most recent studies, Zhu et al. (2017)
examined data from the large U.S. Current Population Survey-
Tobacco Use Supplement (CPS-TUS). The researchers drew on
survey data from more than 160,000 respondents to generate a ret-
rospective cohort of participants who reported having been smok-
ers of traditional cigarettes one year prior to the survey. They
examined the population-level rates of making a quit attempt in the
past year and of quitting smoking. Smokers who used e-cigarettes
during 2014-15 were more likely than non-users to make a quit
attempt and obtain complete smoking cessation. The analysis ver-
ified that the quit rates between smokers of traditional cigarettes
who used or had ever used an e-cigarette showed a smoking cessa-
tion rate increased by 1.1 percentage points between 2010-2011
and 2014-2015. This happened in coincidence with the increase of
e-cigarette use amongst smokers of traditional cigarettes. Hence, in
this study e-cigarettes appear to have helped to improve smoking
cessation rates.
All three of these more recent studies have significant limita-
tions. They are observational in nature and thus cannot determine
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causality. In addition, there was likely to be recall bias amongst
participants in relation to both the extent of e-cigarette use and quit
attempts. Finally, there may be confounders not assessed in the
studies, including lack of information on previous quit attempts,
the type of e-cigarette used, motivation to quit and reasons for e-
cigarette use, for example.
In a very recent fourth study, e-cigarettes usage was almost
twice as effective as NRT to help smokers of traditional cigarettes
quit smoking (Hajek et al., 2019). This multicentre randomised
trial of e-cigarettes versus NRT involved 886 adults attending
smoking cessation services in England. The smokers were ran-
domised with 447 individuals assigned to a NRT group and 439
assigned to an e-cigarette group. Both groups received one-on-one
behavioural counselling each week for four weeks and were bio-
chemically tested at the end of the year to assure they had stopped
smoking. Smokers in the e-cigarette group were given a starter
pack, a 30 mL bottle of tobacco flavoured e-liquid with a nicotine
concentration of 18 mg per mL, and instructions on how to use the
device. Participants were encouraged to use different flavoured e-
liquids with different concentrations of nicotine. Participants in the
NRT group were offered a several products including patches,
gum, lozenges, nasal or mouth sprays, inhalers, mouth strips, or
microtabs and they were encouraged to choose a combination of
products.
The primary outcome was sustained smoking abstinence for
one year, which was biochemically validated during the final visit
of the trial. Secondary outcomes included participant-reported
treatment usage and respiratory symptoms. The researchers
observed a one-year abstinence rate of 18.0% in the e-cigarette
group compared with 9.9% in the NRT group. This study found
that 80% of participants in the e-cigarette group were more likely
to continue using their product at one year compared with 9.0% in
the NRT group. This study had several strong points, including
long-term outcomes with a large sample size, a real life setting,
researchers who let participants choose their e-liquid and their
NRT, biochemical verification of smoking cessation outcomes, and
rigorous data analysis but it’s uncertain if the results would gener-
alize to other populations of smokers. It is also not possible to
affirm that these discoveries would apply to other e-cigarette
devices, or away from the setting of a controlled study and lacking
behavioural counselling.
Conclusions
Although e-cigarettes have not been proven to be totally safe,
evidence suggests that they may be less harmful alternatives to
combustible cigarette smoking. The findings from these studies,
conducted with first generation and second-generation e-
cigarettes, suggests that the provision of e-cigarettes can signifi-
cantly reduce traditional cigarette consumption and CO expired
breath without worsening of general state of health and without
showing significant and serious Adverse Events (AEs).
Consequently, for people who smoke e-cigarettes could be consid-
ered among the applicable tools for THR, well-being and health
empowerment. 
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